IL6 and gastric cancer: Loss of AQP3 might lead to reduced expression of inflammatory factors like IL-6 and TNF-α, and AQP3 inhibition could decrease the production of IL-6, IL-1β, and TNF-α, impairing intestinal bacteria clearance and contributing to gastric cancer progression [55–57].